There is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence .
There is no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later .
BACKGROUND Studies have shown that interventions which reduce total and low-density lipoprotein cholesterol levels also reduce coronary heart disease ( CHD ) and stroke events in those with a history of CHD .
However , it is uncertain whether treatment to alter cholesterol levels can prevent recurrence of either stroke or subsequent cardiovascular events and whether differences in outcomes exist between classes of lipid-lowering therapy .
This is an up date of a Cochrane review first published in 2002 .
OBJECTIVES To investigate the effect of altering serum lipids pharmacologically for preventing subsequent cardiovascular disease and stroke recurrence in patients with a history of stroke .
An evaluation of estrogenic substances in the treatment of cerebral vascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section.
A cooperative clinical investigation was undertaken in 17 Veterans Administration Hospitals to determine the effects of long-term therapy with conjugated equine estrogens ( Premarin ) in prevention of recurrent cerebral infa rct ion or death due to atherosclerotic vascular disease . To date , 582 men with cerebral infa rct ion have been assigned on a r and om basis to either the treatment or control groups and observed for periods as long as 34 months . Initial treatment consisted of 1.25 mg . of Premarin daily and was increased to 2.5 mg . after the first year . Estrogenic therapy failed to reduce the incidence of either cerebral or myocardial infa rct ion developing during the period of follow-up observation . There was likewise no significant change in the mortality rate following onset of therapy . Of the 63 deaths in the study , 34 occurred in patients receiving treatment and 29 among those receiving the placebo preparation . Approximately 40 per cent of patients developed mild side reactions to the estrogenic agent , usually consisting of breast tenderness or enlargement , or both . These preliminary observations failed to demonstrate that treatment with conjugated equine estrogenic hormones in small and moderate dosages for an average period of 16.7 months had any value in lowering the recurrence of cerebral infa rct ion or reducing the mortality rate subsequent to this disorder
There is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence .
There is no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later .
BACKGROUND Studies have shown that interventions which reduce total and low-density lipoprotein cholesterol levels also reduce coronary heart disease ( CHD ) and stroke events in those with a history of CHD .
However , it is uncertain whether treatment to alter cholesterol levels can prevent recurrence of either stroke or subsequent cardiovascular events and whether differences in outcomes exist between classes of lipid-lowering therapy .
This is an up date of a Cochrane review first published in 2002 .
OBJECTIVES To investigate the effect of altering serum lipids pharmacologically for preventing subsequent cardiovascular disease and stroke recurrence in patients with a history of stroke .